Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Viral vectors for malaria vaccine development.

Shengqiang Li1, Emily Locke, Joseph Bruder

  • 1PATH Malaria Vaccine Initiative, Bethesda, MD, USA. sheng.li@hhs.gov

Vaccine
|August 18, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of cross-stage, cross-species malaria CD8<sup>+</sup> T cell antigens.

Nature·2026
Same author

Bivalent virus-like particles expressing SPECT1 and CSP trigger pre-erythrocytic malaria immunity and protect against transgenic <i>Plasmodium falciparum</i> sporozoite challenge in mice.

Frontiers in immunology·2026
Same author

Phase I/IIa study to assess the safety, immunogenicity and efficacy of ChAdOx1-MVA vectored vaccines expressing a novel liver-stage malaria dual antigen LS2 by sporozoite challenge in malaria-naïve adults.

Wellcome open research·2026
Same author

African-specific genetic loci determine iron status and risk of severe malaria and bacteremia in African children.

Nature communications·2026
Same author

Recent Advances, Bottlenecks, and Future Directions in <i>Plasmodium falciparum</i> Vaccine Development.

Vaccines·2026
Same author

B and T cell responses to pre-erythrocytic R21/Matrix-M and blood-stage RH5.1/Matrix-M malaria vaccines in endemic settings.

Frontiers in immunology·2026

Advancements in viral vectors for malaria vaccines show promise. Optimizing Plasmodium gene expression in mammalian cells is key for developing next-generation vaccines.

Area of Science:

  • Vaccinology
  • Virology
  • Parasitology

Background:

  • Viral vectors are crucial for malaria vaccine development.
  • Established vectors like poxvirus, adenovirus, and alphavirus have shown success.
  • Emerging vectors including measles virus (MV), vesicular stomatitis virus (VSV), and yellow fever (YF) virus offer new possibilities.

Purpose of the Study:

  • To discuss recent advancements in viral-vectored malaria vaccine development.
  • To explore emerging viral vector technologies for malaria vaccines.
  • To highlight strategies for optimizing malaria antigen expression and immunogenicity.

Main Methods:

  • Review of recent studies and workshop discussions on viral vector technologies.
  • Analysis of immune responses induced by various viral vectors in animal models and human trials.

Related Experiment Videos

  • Evaluation of Plasmodium gene optimization techniques for enhanced vaccine efficacy.

    • Main Results:

    • Classic viral vectors have successfully delivered malaria antigens, with some candidates showing potential in preclinical and clinical studies.
    • Emerging viral vectors (MV, VSV, YF) demonstrate unique capabilities for inducing humoral and/or cellular immunity.
    • Optimization of Plasmodium genes (e.g., codon optimization, de-glycosylation) can significantly improve immunogenicity.

    Conclusions:

    • Viral vectors offer a viable platform for malaria vaccine development, with diverse vector systems eliciting distinct immune responses.
    • Strategic optimization of malaria antigen expression in mammalian cells is critical for enhancing vaccine efficacy.
    • Further understanding of vector-specific immune induction and antigen expression will guide the design of next-generation malaria vaccines.